Delivery Order SPE2DB20D1004-SPE2DB24FF1Q3
- Not listed
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products. The order has a completion date of February 8, 2024 and a potential value of $1,577.28. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which is not associated with any set-aside designation. Additionally, Amerisourcebergen Drug Corp holds...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $78,864.00 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp by DLA, valued up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary contract vehicle for Amerisourcebergen to deliver...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the leading global pharmaceutical distributor Amerisourcebergen Corporation. The $27,996.72 contract is for the supply of the pharmaceutical product HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, with a completion date of March 4, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as a prime contractor providing a wide range of pharmaceutical products...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The $1,577.28 award has a completion date of February 13, 2024. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00, that serves as the primary vehicle for the company to deliver pharmaceutical products...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The $41,926.39 order is for HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of February 15, 2024. Amerisourcebergen Drug Corp is a for-profit organization that serves as a prime contractor providing a wide range of pharmaceutical products and medical supplies to U.S. government agencies,...
- The U.S. Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation. The $1,182.96 order is for HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of January 19, 2024. AmerisourceBergen Drug Corp, through its Corporate Office division, has been a prime contractor providing pharmaceuticals, medical supplies, and distribution...
- Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a $7,886.40 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of February 12, 2024. This delivery order is part of an indefinite delivery contract (IDC) valued at up to $999,999,999.00 awarded to Amerisourcebergen Drug Corp by DLA, which serves as the primary vehicle for the...
- The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML medical supplies. The $99,634.60 contract has a completion date of December 22, 2023 and was awarded on December 21, 2023. This order is part of Amerisourcebergen's existing indefinite delivery contract with DLA to provide pharmaceuticals and medical supplies, primarily in support of...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $3,154.56 to AmerisourceBergen Drug Corp's Corporate Office division. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, which has a ceiling value of up to $999,999,999 and is in effect through December 2025. The...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of March 1, 2024 and a potential value of $2,365.92. Amerisourcebergen Drug Corp is the prime contractor and there is no set-aside designation for this award. Amerisourcebergen Drug Corp holds an indefinite...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB24FF1Q3Delivery Order
The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceuticals. The order, valued at $7,886.40, has a completion date of January 5, 2024. Amerisourcebergen Drug Corp, a for-profit organization, has a history of supplying pharmaceuticals and medical supplies to DLA Troop Support Medical for military treatment programs. This delivery order was not set aside for any specific business type. Amerisourcebergen Drug Corp also holds an indefinite delivery contract with the Department of Justice Federal Bureau of Investigation Headquarters Division to provide medical supplies and prescription medications, with a potential value of $750,000 through May 2024.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.9k | 1/4/24 |